Significant Significant events after the quarter
events in
Q2

• In · To secure long-time financing of the operations, the Board of

June, Directors decided in July to raise about SEK 74.7 million through
Enzymatica a rights issue. The new issue is 100% guaranteed by subscription
AB signed a commitments together with underwriting agreements from the
loan company's three largest shareholders, as well as the company's
agreement Chairman of the Board and CEO.
with the
three
largest
owners, as
well as the
company's
CEO and
chairman of
the board,
for a
maximum of
SEK 20
million
that can be
used to
support the
company's
liquidity
in periods
with lower
sales.

• In

June, data
from an
ongoing in
vitro study
showed that
ColdZyme
blocks the
omicron
virus from
binding to
human
cells.
Continued
clinical
trials are
needed to
determine
the effect
in humans.

Other events during
and after the
quarter

• In June, the

patent authorities
in Mexico granted
Enzymatica a patent
for the cod trypsin
that is one of the
key components in
ColdZyme. The patent
is valid until 2036.

• The first

delivery was sent to
Mexico in
preparation for
Sanofi's launch on
the Mexican market.
This is the first
time that
Enzymatica's mouth
spray is sold on the
other side of the
Atlantic.

• On July 1,

Enzymatica submitted
its application for
approval of ColdZyme
under the EU's MDR
regulatory
requirements.

Second quarter January-June

• Net sales reached SEK 9.6 (6.1) · Net sales reached SEK 13.8

million. (23.1) million.

• The operating result totaled SEK · The operating result totaled

-15.9 (-20.0) million. SEK -34.0 (-28.7) million.

• Earnings per share, basic and · Earnings per share, basic and

diluted, were SEK -0.10 (-0.14). diluted, were SEK -0.22 (-0.20).
  · Cash flow from operating

• Cash flow from operating activities totaled SEK -31.7

activities totaled SEK -21.5 (-14.4) (-13.1) million.
million.

"During the second quarter, sales in Sweden increased by 222% compared with the same period in 2021 and sales were also higher than the same period in 2020 and 2019. In those markets that are handled by our partners, our sales were on a par with the same period last year. The rights issue that was communicated today puts Enzymatica on solid ground for the years to come, including the possibility of more clinical studies as well as powerful marketing", said Claus Egstrand, CEO of Enzymatica.

The full year-end report is available on: www.enzymatica.com/investors/financial-reports

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET
on 19 July 2022.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: certifiedadviser@penser.se.